Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

OBJECTIVES One potential concern of once-daily protease inhibitor administration is low trough concentrations and ultimately the 'forgiveness' or robustness in comparison with the originally licensed twice-daily dose. To give an estimation of 'forgiveness', we determined the length of time plasma drug concentrations were below target in HIV-infected patients receiving saquinavir/ritonavir regimens. METHODS Seventy-seven pharmacokinetic profiles (saquinavir/ritonavir 1000/100 mg twice daily, n = 34; 1600/100 mg once daily, n = 26; 2000/100 mg once daily, n = 17) from five studies were combined, presented as twice- and once-daily percentiles (P10-P90) and compared. At percentiles where trough concentrations fell below the alleged minimum effective concentration (MEC; 100 ng/mL), the length of time below MEC was determined. RESULTS Saquinavir concentrations were below MEC at P10 for 0.7 h for twice-daily saquinavir/ritonavir when compared with 8.6 and 6.6 h for 1600/100 and 2000/100 mg once daily, respectively. At P25, 1600/100 mg once daily produced suboptimal concentrations for 5.5 h in contrast to 0.5 h for 2000/100 mg once daily. CONCLUSIONS Here, we provide substantive data that indicate once-daily saquinavir, in particular 1600/100 mg, is not as robust as the twice-daily regimen based on a population of UK patients; this raises concern over late or missed doses. However, pharmacokinetic data can only ever be a guide to the impact on long-term efficacy.

[1]  J. Urquhart,et al.  Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  J. Shuter,et al.  HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95% , 2007, Journal of acquired immune deficiency syndromes.

[3]  D. Podzamczer,et al.  A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen , 2006, Journal of acquired immune deficiency syndromes.

[4]  D. Burger,et al.  A Retrospective TDM Database Analysis of Interpatient Variability in the Pharmacokinetics of Lopinavir in HIV-infected Adults , 2006, Therapeutic drug monitoring.

[5]  P. Harrigan,et al.  Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.

[6]  M. Saag,et al.  Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients , 2006, MedGenMed : Medscape general medicine.

[7]  J. Schapiro,et al.  Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .

[8]  S. Khoo,et al.  Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  V. Soriano,et al.  Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral‐experienced HIV‐infected patients , 2005, Journal of medical virology.

[10]  J. Ananworanich,et al.  Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. , 2005, The Journal of antimicrobial chemotherapy.

[11]  B. Hirschel,et al.  A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients , 2005, Antiviral therapy.

[12]  B. Gazzard,et al.  Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. , 2005, The Journal of antimicrobial chemotherapy.

[13]  K. Ruxrungtham,et al.  The 48‐week efficacy of once‐daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy , 2005, HIV medicine.

[14]  B. Gazzard,et al.  Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. , 2005, British journal of clinical pharmacology.

[15]  B. Gazzard,et al.  Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients , 2004, Journal of acquired immune deficiency syndromes.

[16]  B. Hirschel,et al.  Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. , 2004, The Journal of antimicrobial chemotherapy.

[17]  B. Gazzard,et al.  Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients , 2004, Antimicrobial Agents and Chemotherapy.

[18]  D. Katzenstein,et al.  Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. , 2004, The Journal of infectious diseases.

[19]  B. Gazzard,et al.  Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen , 2003, Antiviral therapy.

[20]  F. Brun-Vézinet,et al.  Once-Daily Dosing of Saquinavir Soft-Gel Capsules and Ritonavir Combination in HIV-1-Infected Patients (Imea015 Study) , 2003, Antiviral therapy.

[21]  J. Bartlett.  Atazanavir enhances saquinavir Hard-Gel concentrations in a ritonavir-boosted once-daily regimen , 2004 .

[22]  J. Bartlett,et al.  Dual HIV-1 infection associated with rapid disease progression , 2004 .

[23]  A. Lazzarin,et al.  Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. , 2004, The new microbiologica.

[24]  M. Kurowski,et al.  Pharmacokinetic and tolerability profile of twice‐daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers , 2003, HIV medicine.

[25]  K. Ruxrungtham,et al.  Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. , 2003, Journal of acquired immune deficiency syndromes.

[26]  E. Acosta,et al.  Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  V. Soriano,et al.  Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. , 2002, AIDS.

[28]  K. Ruxrungtham,et al.  Simplifying Protease Inhibitor Therapy with Once‐Daily Dosing of Saquinavir Soft‐Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study , 2002, Journal of acquired immune deficiency syndromes.

[29]  Marilyn M. Wagener,et al.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .

[30]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[31]  H. Wineberg.  Oregon's Death with Dignity Act: fourteen months and counting. , 2000, Archives of internal medicine.